Despite Its Social Media Expertise, J&J Fails to Use It Effectively to Communicate to...
Johnson & Johnson's (JNJ's) has earned accolades from industry pundits for its social media expertise (see Dosie Awards, for example). Yet it's handling of...
Equation Proves that Broadcast DTCA Only a Minor Contributor to Growth in Rx Drug...
In an equation that Einstein would be proud of, researchers at the National Bureau of Economic Research (NBER) supported by a grant from the...
Should Google Allow Pharma an Exception to Its Ban on Redirect URLs? (UPDATED)
Back in April 2009, I suggested that FDA might go after pharma marketers for using paid search redirects in Google Adwords (see "The Next...
Will FDA Cite this Vyvanse Web Image as Off-Label Promotion?
If an image is worth a thousand words, then this image found on the Vyvanse Web site home page is shouting off-label promotion.
Is it...
Pharma Marketing Meets Social Media: Can the Two Co-Habitate?
I am taking a short vacation in Miami and will be chairing the Pharmaceutical Marketing Innovation Summit, May 10 - 12, 2010 at the...
Trouble in the House that McNeil Built: Why Drug Company Silos are Useful
Marc Monseau, head of corporate communications at Johnson & Johnson (J&J or JNJ) and contributor to the JNJBTW Blog, often says that JNJ is...
Is Your Brand a Digital Genius or a Feeble-Minded Idiot?
When it comes to digital IQ, some brands are geniuses and some are feeble-minded idiots, according to the "L2 Digital IQ Index" for pharmaceutical...
Data Mining in the Deep, Dark Social Networks of Patients
If pharma marketers wish to tap into closed online patient communities that are rich sources of information, they need to pay careful attention to the rules lest they suffer the consequences to their reputations.
ePrints NRx for Physician Detailing
This article describes and summarizes the features and benefits of the Reprints Desk's ePrints NRx solution -- a new scientific article collection service that simplifies the re-use of PDFs by medical marketers, brand managers, and sales professionals.
The Changing Pharma Commercial Model in 2010 and Beyond
This article features a summary of the much anticipated NEW Kantar Health TRI*M annual survey results with physicians across the U.S. and Europe on their service expectations -- plus how they rate 16 Pharma companies on reps, relationships and services. The survey looked not only at PCPs/GPs but also -- for the first time -- at what oncologists expect from the industry.
